Germany’s Cannabis Act (CanG) has not led to an increase in use among young people, according to new peer-reviewed research adding to the growing body of evidence contradicting the harms predicted by the reform’s critics.
It’s now five months since the German Federal Cabinet adopted draft amendments to its pivotal Medizinal-Cannabisgesetzes (MedCanG) bill, and its finalisation is expected in the coming weeks.
Germany’s cannabis imports, according to the latest figures from BfArM, nearly tripled in size in 2025, cementing it beyond any doubt as the engine behind Europe’s medical cannabis boom.
Last month (January 15, 2026) Germany’s Bundesrag held a debate on the hotly contested amendments aimed at significantly restricting medical cannabis prescriptions, and potentially transforming the industry.
Today, (Wednesday, January 14), a public hearing will bring together 22 hand-picked experts for a debate on the future country’s near-billion-euro medical cannabis industry.
Germany’s Bundesrat voted on November 21 to support key restrictions on medical cannabis prescribing and distribution, while rejecting proposals to ban prescriptions being sent via mail, a mixed outcome that offers both relief and concern for an industry bracing for regulatory tightening.
Germany’s medical cannabis imports continued their historic run in Q3 of 2025, seeing the country bring in just under 57 tonnes, though growth levels dipped slightly from Q2.
Synbiotic SE German cannabis and hemp group Synbiotic SE has issued a substantial downgrade to both its sales and profit forecasts for the full year 2025 as Germany’s rapidly inflated medical cannabis bubble shows the first signs it could be about to burst.
In Germany, the partial legalisation of cannabis has opened up a new telemedicine market. Instead of visiting a doctor in person, patients can now request prescriptions online, with cannabis flowers sent directly to patients via specialist pharmacies.
